HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-10-23FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for COMPLERA submitted by Gilead Sciences, related to the existing HIV-1 therapy regimen.
-
FDA approval · 2013-10-23FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) from Gilea…
-
FDA approval · 2013-10-16FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for STRIBILD, a fixed-dose combination antiretroviral, to be produced by Gilead Sciences, Inc.
-
FDA approval · 2013-10-02FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for STRIBILD, the fixed-dose combination antiretroviral from Gilead Sciences, Inc. The approval …
-
FDA approval · 2013-09-13FDA Approved: ABACAVIR — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' original application for abacavir, a generic antiretroviral for HIV-1 infection.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-09-11FDA Approved: ZIAGEN — Supplemental Application (ViiV Healthcare Company)
FDA approves a supplemental application for Ziagen (abacavir sulfate) from ViiV Healthcare Company.
-
FDA approval · 2013-08-21FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)
The FDA approved a supplemental application for TRUVADA (emtricitabine and tenofovir disoproxil fumarate) submitted by Gilead Sciences.
-
FDA approval · 2013-08-15FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for Reyataz (atazanavir) submitted by E.R. Squibb & Sons, L.L.C.
-
FDA approval · 2013-08-12FDA Approved: TIVICAY — Original Application (ViiV Healthcare Company)
The FDA approved the original NDA for TIVICAY (dolutegravir), authorizing its use for treating HIV-1 infection. The submission was from ViiV…
-
FDA approval · 2013-08-05FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2013-08-05FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) from Merck Sharp & Dohme LLC, resulting in changes to its labeling.
-
FDA approval · 2013-07-08FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)
The FDA approved a supplemental application for TRUVADA from Gilead Sciences, Inc.
-
FDA approval · 2013-07-08FDA Approved: ETRAVIRINE — Supplemental Application (Patriot Pharmaceuticals)
The FDA approved a supplemental application for ETRAVIRINE submitted by Patriot Pharmaceuticals.
-
FDA approval · 2013-06-28FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) from Merck Sharp & Dohme LLC, signaling an update to its labeling/in…
-
FDA approval · 2013-06-21FDA Approved: EDURANT — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for Edurant (rilpivirine hydrochloride) submitted by Janssen Products, LP. This action confirms regu…
-
FDA approval · 2013-06-20FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate) from …
-
FDA approval · 2013-06-19FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for STRIBILD, a fixed-dose combination antiretroviral, to modify/expand its labeling.
-
FDA approval · 2013-06-17FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)
FDA approved a supplemental application for TRUVADA (emtricitabine/tenofovir disoproxil fumarate) submitted by Gilead Sciences, Inc.
-
FDA approval · 2013-06-14FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for Prezista (darunavir) by Janssen Products LP.
-
FDA approval · 2013-05-28FDA Approved: VIRACEPT — Supplemental Application (AGOURON)
FDA approved a supplemental application for Viracept (nelfinavir mesylate) filed by Agouron.
-
FDA approval · 2013-05-28FDA Approved: VIRACEPT — Supplemental Application (AGOURON)
The FDA approved a supplemental application for Viracept (nelfinavir mesylate) submitted by Agouron.
-
FDA approval · 2013-05-28FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for ISENTRESS (raltegravir) from Merck Sharp & Dohme LLC, indicating an update to the drug's lab…
-
FDA approval · 2013-05-10FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for COMPLERA to update its labeling.
-
FDA approval · 2013-05-03FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) from Gilea…
-
FDA approval · 2013-04-30FDA Approved: ETRAVIRINE — Supplemental Application (Patriot Pharmaceuticals)
The FDA approved a supplemental application for etravirine (ETRAVIRINE) submitted by Patriot Pharmaceuticals. The action pertains to an HIV-…